The Food and Drug Administration (FDA) announced the launch of Task Force “Alectryon” on Thursday, Dec. 28 to focus on the evaluation of avian flu vaccine.

Alectryon is an ancient Greek word, which means “rooster.”

The task force led by FDA Director General Dr. Samuel A. Zacate was established to intensify efforts in the evaluation of vaccines designed to counter the Highly Pathogenic Avian Influenza (HPAI) virus.

Avian influenza, commonly known as “bird flu,” is a highly contagious viral disease with the potential to impact both domestic and wild bird populations.

The virus can also pose a threat to mammal species, including humans, making it imperative to address the associated risks comprehensively.

FDA said the poultry industry is a crucial component of the national economy and faces severe challenges from avian influenza outbreaks.

These outbreaks not only jeopardize farmers' livelihoods but also pose threats to food security and international trade.

While the Philippines successfully managed its first epidemic of HPAI in 2017, the persistent threat of reemergence necessitates continuous vigilance.

It said the widespread infection among bird populations increases the risk of transmission to other species, including economically significant ones, and even to humans.

In response to these challenges, Task Force Alectryon is set to take a proactive approach to manage the spread of the virus effectively. 

The FDA pointed out that the task force's primary focus is on the streamlined evaluation of applications for Avian Influenza (AI) drugs and vaccines.

These evaluations will prioritize products that are deemed safe, efficacious, and of high quality, aiming to prevent and control the spread of the avian flu virus.

Meanwhile, highlighting the importance of vaccination as a crucial component of the strategy, the FDA emphasized the need for a comprehensive approach involving preventive measures and control strategies.

It stressed that the task force will play a pivotal role in ensuring that AI drugs and vaccines meet the necessary standards.

Moreover, the FDA expressed full support for the administration's program aimed at assisting the local poultry industry. 

It said that the goal is to guarantee the availability and affordability of poultry products and by-products, contributing to overall food security.

As of now, the agency said that no application for a Certificate of Product Registration for the AI vaccine has been submitted to the FDA.

It encouraged the veterinary pharmaceutical industry to submit applications promptly, complete with all requirements, to support the government's endeavors in controlling Avian Flu infections.